Page 103 - 《中国药房》2024年6期

参考文献 matoid arthritis[J]. Am Fam Physician，2011，84（11）：
[ 1 ] RADU A F，BUNGAU S G. Management of rheumatoid 1245-1252.
arthritis：an overview[J]. Cells，2021，10（11）：2857. [13] BUCH M H. Defining refractory rheumatoid arthritis[J].
[ 2 ] HUANG J，FU X K，CHEN X X，et al. Promising thera‐ Ann Rheum Dis，2018，77（7）：966-969.
peutic targets for treatment of rheumatoid arthritis[J]. [14] TAYLOR P C，KEYSTONE E C，VAN DER HEIJDE D，
Front Immunol，2021，12：686155. et al. Baricitinib versus placebo or adalimumab in rheuma‐
[ 3 ] DAI Y J，WANG W N，YU Y K，et al. Rheumatoid toid arthritis[J]. N Engl J Med，2017，376（7）：652-662.
arthritis-associated interstitial lung disease：an overview [15] TAKANASHI S，KANEKO Y，TAKEUCHI T. CDAI and
of epidemiology，pathogenesis and management[J]. Clin DAS28 in the management of rheumatoid arthritis in clini‐
cal practice[J]. Ann Rheum Dis，2020，79（5）：671-674.
Rheumatol，2021，40（4）：1211-1220.
[ 4 ] BUCH M H，EYRE S，MCGONAGLE D. Persistent in‐ [16] MEKIC M，HADZIGRAHIC E，DZUBUR A. Relation be‐
tween anti-CCP antibodies and sharp score in rheumatoid
flammatory and non-inflammatory mechanisms in refrac‐
arthritis[J]. Mater Sociomed，2020，32（3）：172-176.
tory rheumatoid arthritis[J]. Nat Rev Rheumatol，2021，17
[17] DING Q，HU W，WANG R，et al. Signaling pathways in
（1）：17-33.
rheumatoid arthritis：implications for targeted therapy[J].
[ 5 ] GUADAGNIN D A，MAZZALI L V，SKARE T L，et al.
Signal Transduct Target Ther，2023，8（1）：68.
Treating rheumatoid arthritis with leflunomide mono‐
[18] MELVILLE A R，KEARSLEY-FLEET L，BUCH M H，et
therapy versus combination therapy with methotrexate[J].
al. Understanding refractory rheumatoid arthritis：implica‐
Eur J Rheumatol，2021，8（1）：12-15.
tions for a therapeutic approach[J]. Drugs，2020，80（9）：
[ 6 ] BARBULESCU A，ASKLING J，CHATZIDIONYSIOU
849-857.
K，et al. Effectiveness of baricitinib and tofacitinib com‐
[19] WAN R H，FAN Y H，ZHAO A L，et al. Comparison of ef‐
pared with bDMARDs in RA：results from a cohort study
ficacy of acupuncture-related therapy in the treatment of
using nationwide Swedish register data[J]. Rheumatology，
rheumatoid arthritis：a network meta-analysis of rando-
2022，61（10）：3952-3962.
mized controlled trials[J]. Front Immunol，2022，13：829409.
[ 7 ] BERTOLDI I，CAPORALI R. Tofacitinib：real-world data
[20] 蒋总，姚晓玲，唐芳，等 . JAK 抑制剂托法替布治疗类风
and treatment persistence in rheumatoid arthritis[J]. Open
湿关节炎相关间质性肺病的实验研究[J]. 安徽医科大学
Access Rheumatol，2021，13：221-237.
学报，2023，58（5）：819-823.
[ 8 ] SCHREZENMEIER E，DÖRNER T. Mechanisms of ac‐
JIANG Z，YAO X L，TANG F，et al. Experimental study
tion of hydroxychloroquine and chloroquine：implications
on the treatment of rheumatoid arthritis associated inter-
for rheumatology[J]. Nat Rev Rheumatol，2020，16（3）：
stitial pulmonary disease with JAK inhibitor tofacitinib[J].
155-166.
Acta Univ Med Anhui，2023，58（5）：819-823.
[ 9 ] VARMA V R，DESAI R J，NAVAKKODE S，et al.
[21] HODGE J A，KAWABATA T T，KRISHNASWAMI S，et
Hydroxychloroquine lowers Alzheimer’s disease and
al. The mechanism of action of tofacitinib：an oral Janus
related dementias risk and rescues molecular phenotypes
kinase inhibitor for the treatment of rheumatoid arthritis
related to Alzheimer’s disease[J]. Mol Psychiatry，2023，
[J]. Clin Exp Rheumatol，2016，34（2）：318-328.
28（3）：1312-1326. [22] DAMSKY W，WANG A，KIM D J，et al. Inhibition of
[10] LYU X，ZENG L Z，ZHANG H，et al. Hydroxychloro‐ type 1 immunity with tofacitinib is associated with marked
quine suppresses lung tumorigenesis via inducing FoxO3a improvement in longstanding sarcoidosis[J]. Nat Commun，
nuclear translocation through STAT3 inactivation[J]. Life 2022，13（1）：3140.
Sci，2020，246：117366. [23] FLEISCHMANN R，KREMER J，TANAKA Y，et al. Effi‐
[11] BAI W，YANG F，XU H J，et al. A multi-center，open- cacy and safety of tofacitinib in patients with active rheu‐
label，randomized study to explore efficacy and safety of matoid arthritis：review of key phase 2 studies[J]. Int J
baricitinib in active primary Sjogren’s syndrome patients Rheum Dis，2016，19（12）：1216-1225.
[J]. Trials，2023，24（1）：112. （收稿日期：2023-09-23 修回日期：2024-02-28）
[12] WASSERMAN A M. Diagnosis and management of rheu‐ （编辑：陈 宏）

中国药房 2024年第35卷第6期 China Pharmacy 2024 Vol. 35 No. 6 · 733 ·